유럽의 디지털 PCR 시장 : 용도별, 최종사용자별, 국가별 - 분석과 예측(2024-2034년)

Introduction to Europe Digital PCR Market

The Europe digital PCR (d-PCR) market is projected to reach $762.7 million by 2034 from $183.9 million in 2024, growing at a CAGR of 15.29% during the forecast period 2024-2034. The market for digital PCRs in Europe has grown by double digits due to the increasing use of personalised medicine for genetic disorder screening and diagnosis. This patient-specific strategy relies heavily on digital PCR (dPCR), which accurately identifies and measures uncommon genetic mutations connected to a range of cancers. Furthermore, the need for quick and precise diagnostic solutions is being fuelled by the growing incidence of infectious diseases throughout Europe. The market's growth in Europe is being greatly aided by technological advancements like droplet digital PCR, nanoplate technology, and microfluidic platforms, which are improving dPCR capabilities.

Market Introduction

The market for digital PCR is growing quickly in Europe due to the growing use of personalised medicine and the need for extremely accurate diagnostics. With its remarkable sensitivity and specificity, digital PCR (dPCR) is especially useful for identifying low-abundance genetic mutations and measuring biomarkers that are essential for early diagnosis and treatment monitoring. Increasing rates of infectious diseases, genetic disorders, and cancers have prompted investments in cutting-edge molecular diagnostic technologies.

The accuracy, throughput, and ease of integration of assays into clinical workflows have been greatly enhanced by technological advancements like droplet digital PCR, nanoplate technology, and microfluidic platforms. Furthermore, market adoption has accelerated throughout the continent due to government initiatives, favourable regulatory frameworks, and increased funding for healthcare infrastructure. The European digital PCR market is expected to grow steadily as top research institutes and business leaders keep working together to create reliable, patient-specific diagnostic solutions. In addition to changing the molecular diagnostics landscape, this dynamic market is opening the door for individualised treatment plans that improve patient outcomes.

Overall, the convergence of technological innovation, regulatory support, and evolving clinical demands is driving the digital PCR market's robust expansion in Europe. Additionally, growing research collaborations and investments will further integrate digital PCR in Europe.

Market Segmentation:

Segmentation 1: by Application

• Clinical and Research Application
• Environmental Application
• Other Application

Segmentation 2: by End User

• Academic and Research Institutes
• Hospitals and Clinics
• Diagnostic Centers
• Pharmaceutical and Biopharmaceutical Companies
• Other End User

Segmentation 3: by Region

• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe digital PCR market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the maximum number of key developments.

Competitive Strategy: The Europe digital PCR market has numerous established players with product portfolios. Key players in the Europe digital PCR market analyzed and profiled in the study involve established players offering products for digital PCR.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• QIAGEN N.V.
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Stilla Technologies Inc.
• SAGA Diagnostics AB
• JETA Molecular BV.

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Market Overview
  • 1.1.1 Workflow of Digital PCR
  • 1.1.2 Comparison of qPCR and dPCR
• 1.2 Trends: Current and Future Impact Assessment
  • 1.2.1 Integration with Next-Generation Sequencing (NGS)
  • 1.2.2 Increased Real-time Monitoring and Point-of-care Applications of Digital PCR
  • 1.2.3 Increasing Product Launches in d-PCR Ecosystem
• 1.3 Supply Chain Overview
• 1.4 Research and Development Review
  • 1.4.1 Patent Filing Trend (by Region)
  • 1.4.2 Patent Filing Trend (by Country)
  • 1.4.3 Patent Filing Trend (by Year)
• 1.5 Ongoing Digital PCR Clinical Trials
• 1.6 Regulatory Landscape
  • 1.6.1 European Union
• 1.7 Market Dynamics Overview
  • 1.7.1 Market Drivers
    • 1.7.1.1 Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Genetic Disorders such as Rare Diseases and Cancer
    • 1.7.1.2 Increasing Incidence of Infectious Diseases
    • 1.7.1.3 Technological Advancement in dPCR to Enhance Market Growth
  • 1.7.2 Market Restraints
    • 1.7.2.1 High Cost of Platforms Associated with Digital-PCR
    • 1.7.2.2 Shortage of Skilled Professionals and Trained Laboratory Technicians
  • 1.7.3 Market Opportunities
    • 1.7.3.1 Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan
    • 1.7.3.2 Growing Adoption of dPCR in Emerging Markets

2 Regions

• 2.1 Regional Summary
• 2.2 Drivers and Restraints
• 2.3 Europe
  • 2.3.1 Regional Overview
  • 2.3.2 Driving Factors for Market Growth
  • 2.3.3 Factors Challenging the Market
  • 2.3.4 By Application
  • 2.3.5 By End User
  • 2.3.6 France
  • 2.3.7 Germany
  • 2.3.8 U.K.
  • 2.3.9 Spain
  • 2.3.10 Italy
  • 2.3.11 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Product Launch and Approval Activities
  • 3.1.4 Expansion, Funding, and Other Activities
• 3.2 Market Share Analysis
• 3.3 Company Profile
  • 3.3.1 QIAGEN N.V.
    • 3.3.1.1 Overview
    • 3.3.1.2 Top Products/Product Portfolio
    • 3.3.1.3 Top Competitors
    • 3.3.1.4 Target Customers
    • 3.3.1.5 Key Personnel
    • 3.3.1.6 Analyst View
  • 3.3.2 F. Hoffmann-La Roche Ltd
    • 3.3.2.1 Overview
    • 3.3.2.2 Top Products/Product Portfolio
    • 3.3.2.3 Top Competitors
    • 3.3.2.4 Target Customers
    • 3.3.2.5 Key Personnel
    • 3.3.2.6 Analyst View
  • 3.3.3 Merck KGaA
    • 3.3.3.1 Overview
    • 3.3.3.2 Top Products/Product Portfolio
    • 3.3.3.3 Top Competitors
    • 3.3.3.4 Target Customers
    • 3.3.3.5 Key Personnel
    • 3.3.3.6 Analyst View
  • 3.3.4 Stilla Technologies Inc.
    • 3.3.4.1 Overview
    • 3.3.4.2 Top Products/Product Portfolio
    • 3.3.4.3 Top Competitors
    • 3.3.4.4 Target Customers
    • 3.3.4.5 Key Personnel
    • 3.3.4.6 Analyst View
  • 3.3.5 SAGA Diagnostics AB
    • 3.3.5.1 Overview
    • 3.3.5.2 Top Products/Product Portfolio
    • 3.3.5.3 Top Competitors
    • 3.3.5.4 Target Customers
    • 3.3.5.5 Key Personnel
    • 3.3.5.6 Analyst View
  • 3.3.6 JETA Molecular BV.
    • 3.3.6.1 Overview
    • 3.3.6.2 Top Products/Product Portfolio
    • 3.3.6.3 Top Competitors
    • 3.3.6.4 Target Customers
    • 3.3.6.5 Key Personnel
    • 3.3.6.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast